ReviewTherapeutic advances in drug safety2011
Safety of drugs used in the treatment of osteoporosis.
Review in Therapeutic advances in drug safety, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Blackcurrants Reduce the Risk of Postmenopausal Osteoporosis: A Pilot Double-Blind, Randomized, Placebo-Controlled Clinical Trial.Nutrients · 2022Trial
- Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [Nuclear medicine and biologyTrial
- Amelioration of Post-traumatic Osteoarthritis by Iontophoretic Liposomal Strontium Ranelate Collaborated with Low-Intensity Pulsed Ultrasound in Rats.International journal of molecular sciences · 2025Article
- Licochalcone D inhibits osteoclast differentiation and postmenopausal osteoporosis by inactivating the NF-κB signaling pathway.Journal of orthopaedic surgery and research · 2025Article
- Characterization and preparation of food-derived peptides on improving osteoporosis: A review.Food chemistry: X · 2024Article
- Insights into the Mechanism of Osteoporosis and the Available Treatment Options.Current pharmaceutical biotechnology · 2024Review
- Antiresorptive agents enhance ossification of free flap reconstructions of the mandible: a radiological retrospective cohort study.Frontiers in oncology · 2024Article
- Non-biological Antiresorptive: Bisphosphonates.Indian journal of orthopaedics · 2023Review
- Osthole Inhibits M1 Macrophage Polarization and Attenuates Osteolysis in a Mouse Skull Model.Oxidative medicine and cellular longevity · 2023Article
- The Senolytic Drug Fisetin Attenuates Bone Degeneration in theJournal of osteoporosis · 2023Article
- Beneficial effect of pristimerin against the development of osteoporosis in ovariectomy-induced osteoporosis rats by the RANKL/TRAF6/NF-κB pathway.Archives of medical science : AMS · 2022Article
- Inflammatory conversion of quiescent osteoblasts by metastatic breast cancer cells through pERK1/2 aggravates cancer-induced bone destruction.Bone research · 2021Article
- Natural medicine delivery from biomedical devices to treat bone disorders: A review.Acta biomaterialia · 2021Review
- Nicorandil Inhibits Osteoclast Formation Base on NF-κB and p-38 MAPK Signaling Pathways and Relieves Ovariectomy-Induced Bone Loss.Frontiers in pharmacology · 2021Article
- Electrical Stimulation of Adipose-Derived Stem Cells in 3D Nanofibrillar Cellulose Increases Their Osteogenic Potential.Biomolecules · 2020Article
- Suppression of Inflammation, Osteoclastogenesis and Bone Loss by PZRAS Extract.Journal of microbiology and biotechnology · 2020Article
- Association of use of Chinese herbal medicines and the risk of fracture in patients with osteoporosis: a population-based cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Article
- The ameliorating effect of the combined extract from GreekRSC advances · 2018Article
- Inhaled corticosteroids and bone health.The open respiratory medicine journal · 2014Article
- The association between serious upper gastrointestinal bleeding and incident bisphosphonate use: a population-based nested cohort study.BMC geriatrics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A number of drug classes are licensed for the treatment of osteoporosis including bisphosphonates, recombinant human parathyroid hormone (PTH), strontium, hormone replacement therapy (HRT), selective oestrogen receptor modulators (SERMS) and denosumab. This review discusses the safety of osteoporosis treatments and their efficacies. Recent concerns about the safety of calcium and high-dose vitamin D are discussed. Bisphosphonates have substantial postmarketing experience and a clearer picture of safety issues is emerging. Along with the well recognized effects on the gastrointestinal tract and kidney function, recently described adverse effects such as osteonecrosis of the jaw, oesophageal cancer, atrial fibrillation, subtrochanteric femur fractures and ocular complications of bisphosphonate therapy are discussed. Therapy with PTH is limited to two years' duration because of the development of osteogenic sarcomas in animal studies, which appeared related to dose, duration and timing of therapy. Strontium should be used with caution in patients with renal impairment and its use has been associated with venous thromboembolism. The role of HRT and SERMs in the treatment of postmenopausal osteoporosis is restricted as a result of an increased risk of stroke, venous thromboembolism and breast cancer. Postmarketing experience with denusomab is limited but a number of potential safety concerns including osteonecrosis of the jaw are emerging. All of these drugs have been proven to reduce fractures. The decision to use a drug to reduce fracture risk should be based on risk-benefit analysis of the drug and its suitability for individual patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.